On September 8, 2025, BioNTech SE presented positive interim data from a Phase 2 trial evaluating pumitamig for small cell lung cancer, showing encouraging antitumor activity.
AI Assistant
BIONTECH SE
2025
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.